Role of interleukin (IL-10) in probiotic-mediated immune modulation: an assessment in wild-type and IL-10 knock-out mice
Open Access
- 27 March 2006
- journal article
- Published by Oxford University Press (OUP) in Clinical and Experimental Immunology
- Vol. 144 (2), 273-280
- https://doi.org/10.1111/j.1365-2249.2006.03051.x
Abstract
While the impact of Bifidobacterium infantis 35624 and other probiotics on cytokines has been shown in established colitis, the effects of B. infantis consumption in pre-inflammation of interleukin (IL)-10 knock-out (KO) mice and on the wild-type (WT) C57Bl/6 mice have not been well demonstrated. The objective of this study was to examine cytokine responses in mucosal and systemic lymphoid compartments of IL-10 KO mice early in disease and to compare with control WT mice. Mice were fed B. infantis or placebo for 5 weeks and culled prior to the onset of chronic intestinal inflammation (12–14 weeks). The spleen, Peyer's patches and intestinal mucosa were removed and stimulated with various bacterial stimuli. Cytokine levels were measured by enzyme-linked immunosorbent assay. While basal intestinal and systemic cytokine profiles of WT and IL-10 KO mice were similar, transforming growth factor (TGF)-β was reduced in the spleen of IL-10 KO mice. Following probiotic consumption, interferon (IFN)-γ was reduced in the Peyer's patch of both WT and IL-10 KO mice. Alterations in IFN-γ in the Peyer's patches of WT mice (enhancement) versus IL-10 KO (reduction) were observed following in vitro stimulation with salmonella. Differential IL-12p40, CCL2 and CCL5 responses were also observed in IL-10 KO mice and WT mice. The cytokine profile of IL-10 KO mice in early disease was similar to that of WT mice. The most pronounced changes occurred in the Peyer's patch of IL-10 KO mice, suggesting a probiotic mechanism of action independent of IL-10. This study provides a rationale for the use of B. infantis 35624 for the treatment of gastrointestinal inflammation.Keywords
This publication has 52 references indexed in Scilit:
- Microbes, immunoregulation, and the gutGut, 2005
- Physiological Basis for Novel Drug Therapies Used to Treat the Inflammatory Bowel Diseases I. Pathophysiological basis and prospects for probiotic therapy in inflammatory bowel diseaseAmerican Journal of Physiology-Gastrointestinal and Liver Physiology, 2005
- Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazineGut, 2004
- Is the mucosal route of administration essential for probiotic function? Subcutaneous administration is associated with attenuation of murine colitis and arthritisGut, 2004
- Probiotics in inflammatory bowel disease—therapeutic rationale and roleAdvanced Drug Delivery Reviews, 2004
- Targeting enteric bacteria in treatment of inflammatory bowel diseasesCurrent Opinion in Gastroenterology, 2003
- Amelioration of Murine Colitis by Feeding a Solution of LysedEscherichia coliScandinavian Journal of Gastroenterology, 2003
- Lactobacillus species prevents colitis in interleukin 10 gene–deficient miceGastroenterology, 1999
- Enterocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4(+) TH1-like responses.JCI Insight, 1996
- Interleukin-10-deficient mice develop chronic enterocolitisCell, 1993